These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37611432)
41. Immunotherapy of breast cancer. Wright SE Expert Opin Biol Ther; 2012 Apr; 12(4):479-90. PubMed ID: 22413825 [TBL] [Abstract][Full Text] [Related]
42. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509 [TBL] [Abstract][Full Text] [Related]
43. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470 [TBL] [Abstract][Full Text] [Related]
44. Vaccine Therapies for Cancer: Then and Now. Morse MA; Gwin WR; Mitchell DA Target Oncol; 2021 Mar; 16(2):121-152. PubMed ID: 33512679 [TBL] [Abstract][Full Text] [Related]
45. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U Front Immunol; 2020; 11():895. PubMed ID: 32528470 [TBL] [Abstract][Full Text] [Related]
46. The development and use of the E75 (HER2 369-377) peptide vaccine. Clifton GT; Peoples GE; Mittendorf EA Future Oncol; 2016 Jun; 12(11):1321-9. PubMed ID: 27044454 [TBL] [Abstract][Full Text] [Related]
47. Immunologic approaches to breast cancer treatment. Sabel MS; Nehs MA Surg Oncol Clin N Am; 2005 Jan; 14(1):1-31, v. PubMed ID: 15541997 [TBL] [Abstract][Full Text] [Related]
48. Breast cancer vaccines: promise for the future or pipe dream? Mittendorf EA; Peoples GE; Singletary SE Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371 [TBL] [Abstract][Full Text] [Related]
49. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Morse MA; Wei J; Hartman Z; Xia W; Ren XR; Lei G; Barry WT; Osada T; Hobeika AC; Peplinski S; Jiang H; Devi GR; Chen W; Spector N; Amalfitano A; Lyerly HK; Clay TM Int J Cancer; 2010 Jun; 126(12):2893-903. PubMed ID: 19856307 [TBL] [Abstract][Full Text] [Related]
50. Immunotherapy in breast cancer: Current status and future directions. Basu A; Ramamoorthi G; Jia Y; Faughn J; Wiener D; Awshah S; Kodumudi K; Czerniecki BJ Adv Cancer Res; 2019; 143():295-349. PubMed ID: 31202361 [TBL] [Abstract][Full Text] [Related]
51. The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants. Ding J; Zheng Y; Wang G; Zheng J; Chai D Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188763. PubMed ID: 35872287 [TBL] [Abstract][Full Text] [Related]
52. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. Jiang XP; Yang DC; Elliott RL; Head JF Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821 [TBL] [Abstract][Full Text] [Related]
53. Developing anti-HER2 vaccines: Breast cancer experience. Al-Awadhi A; Lee Murray J; Ibrahim NK Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245 [TBL] [Abstract][Full Text] [Related]
54. Adjuvant HER2/neu peptide cancer vaccines in breast cancer. Clifton GT; Mittendorf EA; Peoples GE Immunotherapy; 2015; 7(11):1159-68. PubMed ID: 26567563 [TBL] [Abstract][Full Text] [Related]
55. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245 [TBL] [Abstract][Full Text] [Related]
56. Current immunotherapeutic strategies in breast cancer. Carson WE; Liang MI Surg Oncol Clin N Am; 2007 Oct; 16(4):841-60, ix. PubMed ID: 18022548 [TBL] [Abstract][Full Text] [Related]
57. Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine. Wang W; Li Y; Wang Y; Ren S; Li Y; Wang B Int Immunopharmacol; 2018 Jan; 54():95-102. PubMed ID: 29112895 [TBL] [Abstract][Full Text] [Related]
58. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. Davodabadi F; Sarhadi M; Arabpour J; Sargazi S; Rahdar A; Díez-Pascual AM J Control Release; 2022 Sep; 349():844-875. PubMed ID: 35908621 [TBL] [Abstract][Full Text] [Related]
59. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. Chamani R; Ranji P; Hadji M; Nahvijou A; Esmati E; Alizadeh AM Eur J Pharmacol; 2018 Jul; 831():87-93. PubMed ID: 29753042 [TBL] [Abstract][Full Text] [Related]
60. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]